Market Overview

Glaxo, Theravance Confirm BREO ELLIPTA Gained US FDA Approval for Treatment of COPD

Share:
Related GSK
Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices
New Potential HIV Vaccine Drug 'Absolutely 100% Effective' In Monkeys
Clinical Trial Patients' Positive Experiences Bode Well For Genocea's Billion Dollar HSV Drug (Seeking Alpha)
Related THRX
Morning Market Losers
18 Biotech Stocks These Wall Street Analysts Are Tracking
Volatile Theravance Inc. Offers Attractive Total Returns Potential (Seeking Alpha)

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO(TM) ELLIPTA(TM) as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. BREO ELLIPTA is a combination of the inhaled corticosteroid (ICS), fluticasone furoate "FF", and the long-acting beta2 agonist (LABA), vilanterol "VI" (FF/VI 100/25 mcg).

Posted-In: News FDA

 

Related Articles (THRX + GSK)

Around the Web, We're Loving...